A Study on the Role of Thrombophilic Genetic Disorders as a Risk Factor for Thrombotic Complications in Patients with Myeloproliferative Disorders

Open access

Summary

Myeloproliferative neoplasms (MPN) are haematological diseases, characterized by clonal hematopoiesis. Hemostasis abnormalities are among the most critical and frequent complications, affecting the quality of life and a possible reason for death. Thrombotic complications are common and multifactorial. Our aim was to study some genetic thrombophilia factors – Factor V Leiden (FVL), G20210A mutation in prothrombin gene (PR G20210A) and PLA2 allele polymorphism of glycoprotein IIIa gene (GPIIIa gene), and their frequency and association with thrombotic risk in both Philadelphia-positive and Philadelphia-negative MPN – chronic myelogenous leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary and secondary myelofibrosis (MF). In our patient population, PLA2 allele polymorphism of GPIIIa gene proved to be the most common and significantly associated with thrombotic complications – 26.85% of our patients were carriers, and 24.14% of them reported thrombotic complications.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1. Gercheva-Kyuchukova L. [Chronic myeloproliferative neoplasms]. 1st ed. Pleven: Peychinski. 2016. Bulgarian.

  • 2. Lutzkanova E Marinova I Pavlova D Todorov V Tzvetkov N. [Hematology]. In: Internal diseases part II – medical student book. 1st ed. Pleven: Medical University; 2012 p. 320-34. Bulgarian.

  • 3. Aftab A Naghmi A Hassan K. Portal vein thrombosis in a case of chronic myeloid leukemia – a rare association. JIMDC.2013;2(4):87-9.

  • 4. Jain A Gupta N Singh T Agarwal S. A study of haemostatic parameters in patients of chronic myeloid leukaemia. J Clin Diagn Res. 2016;10(7):0C19-0C23.

  • 5. Sora F Iurlo A Sica S Latagliata R Annunziata M Galimberti S et al. Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence clinical findings and outcome. Br J Haematol. 2018;181(2):267-70.

  • 6. Lad DP Jain A Varma S. Complications and management of coagulation disorders in leukemia patients. Dovepress. 2017;7:61-72.

  • 7. Elliott MA Tefferi A. Thrombosis and hemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2004;128(3):275-90.

  • 8. Sykes TC Fegan C Mosquera D. Thrombophilia polymorphisms and vascular disease. Mol Pathol. 2000;53(6):300-6.

  • 9. Stefano V Rossi E Paciaroni K Leone G. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica. 2002;87(10):1095-108.

  • 10. Foy P Moll S. Thrombophilia: 2009 update. Curr Treat Options Cardiovasc Med. 2009;11(2):114-28.

  • 11. Kottke-Marchant K. Genetic polymorphisms associated with venous and arterial thrombosis. Arch Pathol Lab Med. 2002;126(3):295-304.

  • 12. Antonov A Kovacheva K Ivanov P Tsvetkov N Komsa-Penkova R Slavcheva V et al. Genetic thrombophilic defects and risk of thrombotic complications in patients with essential thrombocythemia and polycythemia vera Part II. Contribution of the genetic thrombophilic defects to the thrombotic risk [Internet] [cited 2019 Jun 24]. Available at: https://www.researchgate.net/publication/290579253

  • 13. Baglin T Gray E Greaves M Hunt BJ Keeling D Machin S et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol. 2010;149(2):209-20.

  • 14. Maidstone and Tunbridge Wells NHS. Guidelines for thrombophilia testing. [Internet]. [cited 2019 Jun 20]. Available from: https://www.mtw.nhs.uk/wp-content/uploads/2015/09/Guidelines-for-Thrombophilia-Testing1.pdf

  • 15. Stevens SM Woller SC Bauer KA Kasthuri R Cushman M Michael Streiff et al. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016;41(1):154-64.

  • 16. Voelkerding KV Wu L Williams EC Hoffman SM Sabatini LM Borcherding WR et al. Factor V R506Q gene mutation analysis by PCR-RFLP – optimization comparison with functional testing for resistance to activated protein C and establishment of cell line controls. Am J Clin Pathol. 1996;106(1):100-6.

  • 17. Jebeleanu G Procopciuc L. G20210A prothrombin gene mutation identified in patients with venous leg ulcers. J Cell Mol Med. 2001;5(4):397-401.

  • 18. Potapov EV Ignatenko S Nasseri BA Loebe M Harke C Bettmann M et al. Clinical significance of PlA polymorphism of platelet GP IIb/IIIa receptors during long-term VAD support. Ann Thorac Surg. 2004;77(3):869-74.

  • 19. Samani NJ Lodwick D. Glycoprotein IIIa polymorphism and risk of myocardial infarction. Cardiovasc Res. 1997;33(3):693-7.

  • 20. Khan S. Dickerman JA. Hereditary thrombophilia. Thromb J. 2006;4(15):1-17.

  • 21. Bertina RM. Factor V Leiden and other coagulation risk factor mutations affecting thrombotic risk. Clin Chem. 1997;43(9):1678-83.

  • 22. Zoeller B Andreas H García de Frutos P Dahlback B. Thrombophilia as a multigenic disease. Haematologica. 1999;84(1):59-70.

  • 23. Hoerl HD Tabares A Kottke-Marchant K. The diagnosis and clinical manifestations of activated protein C resistance: a case report and review of the literature. Vasc Med. 1996. 1(4):275-80.

  • 24. Rees DC Cox M Clegg JB. World distribution of factor V Leiden. Lancet. 1995;346(8983):1133-4.

  • 25. Bertina RM Koeleman BP Koster T Rosendaal FR Dirven RJ de Ronde H. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64-7.

  • 26. Jensen MK de Nully Brown P Thorsen S Hasselbalch HC. Frequent occurrence of anticardiolipin antibodies Factor V Leiden mutation and perturbed endothelial function in chronic myeloproliferative disorders. Am J Hematol. 2002;69(3):185-91.

  • 27. Trifa AP Cucuianu A Popp RA Coada CA Costache RM Militaru MS et al. Therelationship between factor V Leiden prothrombin G20210A and MTHFR mutations and the first major thrombotic episode in polycythemia vera and essential thrombocythemia. Ann Hematol. 2014;93(2):203-9

  • 28. Ruggeri M Gisslinger H Tosetto A Rintelen C Mannhalter C Pabinger I et al. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol. 2002;71(1):1-6.

  • 29. Afshar-Kharghan V López JA Gray LA Padilla A Borthakur G Roberts SC et al. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis. 2004;15(1):21-4.

  • 30. Rosendaal FR Doggen CJ Zivelin A Arruda VR Aiach M Siscovick DS et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost. 1998;79(4):706-8.

  • 31. Leroyer C Mercier B Oger E Chenu E Abgrall JF Férec C et al. Prevalence of the 20210A allele of the prothrombin gene in venous thromboembolism patients. Thromb Haemost. 1998;80(1):49-51.

  • 32. Rosendaal FR. Venous thrombosis: the role of genes environment and behavior. Hematology Am Soc Hematol Educ Program. 2005 1-12.

  • 33. Poort SR Rosendaal FR Reitsma PH Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88(10):3698-703.

  • 34. Gisslinger H Müllner M Pabinger I Heis-Vahidi-Fard N Gisslinger B Brichta A et al. Mutation of the prothrombin gene and thrombotic events in patients with polycythemia vera or essential thrombocythemia: a cohort study. Haematologica. 2005;90(3):408-10.

  • 35. Bray PF. Integrin polymorphisms as risk factors for thrombosis. Thromb Haemost. 1999. 82(2):337-44.

  • 36. Burr D Doss H Cooke GE Goldschmidt-Clermont PJ. A meta-analysis of studies on the association of the platelet PlA polymorphism of glycoprotein IIIa and risk of coronary heart disease. Stat Med. 2003;22(10):1741-60.

Search
Journal information
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 27 27 23
PDF Downloads 29 29 27